Physician profile
Amy B Smith
NPI 1588686968
$9,384.79
in general payments reported to CMS, 2019-2025
29 companies · $1,185 in 2025
The $1,185 reported for 2025 was more than what 83% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,696 · 2022: $2,316 · 2023: $1,468 · 2024: $1,720 · 2025: $1,185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,021 · Education: $352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,020.79 |
| Education | $351.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,556.99 | 2021-2025 | Tremfya |
| Abbvie INC. | $1,881.47 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $639.48 | 2021-2025 | Ilumya |
| Lilly USA, LLC | $442.59 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $348.10 | 2021-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $298.39 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $231.71 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $228.42 | 2021-2025 | Adbry, Anzupgo |
| Incyte Corporation | $218.99 | 2021-2025 | Opzelura |
| Genzyme Corporation | $175.79 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $160.71 | 2022-2025 | Cabtreo, Siliq |
| Janssen Scientific Affairs, LLC | $153.51 | 2021-2022 | |
| Epi Health, LLC | $140.21 | 2021 | |
| Pfizer INC. | $139.52 | 2021-2025 | |
| Galderma Laboratories, L.P. | $134.36 | 2021-2025 | Aklief, Nemluvio |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $118.43 | 2021-2023 | Poteligeo |
| Arcutis Biotherapeutics, INC. | $100.44 | 2023-2024 | Zoryve |
| Sanofi-Aventis U.S. LLC | $79.99 | 2021 | |
| Biofrontera INC. | $67.74 | 2021-2022 | |
| Nabriva Therapeutics, Plc | $46.13 | 2021-2022 | |
| Genentech USA, INC. | $40.85 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $36.22 | 2022 | |
| Organon LLC | $30.04 | 2025 | |
| Almirall LLC | $24.02 | 2022 | |
| Amgen INC. | $22.03 | 2024 | Otezla |
| Biocon Biologics INC | $21.99 | 2023 | Hulio |
| Helsinn Therapeutics (U.S.), INC. | $16.08 | 2023 | Valchlor |
| Stemline Therapeutics INC. | $15.79 | 2022 | |
| Dermavant Sciences, INC. | $14.80 | 2024 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.